MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$2.78 USD
0.00 (0.00%)
Updated Jun 25, 2024 10:38 AM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
Brokerage Reports
MEI Pharma, Inc. [MEIP]
Reports for Purchase
Showing records 121 - 140 ( 141 total )
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Analyst Day Summary; Busy 2014; Big Catalysts In Sight
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Positive AGM Update; Analyst Day Next Week; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Initiating Coverage with an OUTPERFORM Rating and $12 Price Target: Best in Class Pracinostat Should Shine
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Intriguing ME-344 Data; Target Upped to $20 on Pipeline Entirety
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
PI3K Inhibitor Acquired; Pracinostat Chugging Along; Nice Positioning
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Takeaways From the 25th ROTH Conference; Reiterate Buy and $16 PT
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Management Update; Fine Tuning Pracinostat''s Path; Target Upped to $16
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Promising Pracinostat Data at ASH Setting Pivotal Stage; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Healthcare -ASH 2012 Preview: Expecting Exciting Data in Atlanta
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Financing Risk Removed and Looking Toward ASH; Target to $2.50
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
European Patent Issued for ME-344; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
F2012 Results; Ramping Up Clinical Programs Nicely
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Pracinostat Acquisition Set to Synergize with Oncology Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J